BACKGROUND: This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK-0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis. OBJECTIVE: This study aimed to investigate the clinical utility of WT1 mRNA expression levels. METHODS: After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. RESULTS: When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and 10 4 copies/µg RNA groups and between the 500-10 4 and 10 4 copies/µg RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid leukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 10 4 copies/µg RNA) was a strong prognostic factor for a short time to AML transformation.
Introduction
High expression levels of Wilms tumor 1 (WT1) mRNA have been reported not only in patients with acute myeloid leukemia (AML), but also in those with myelodysplastic syndrome (MDS) [1] [2] [3] [4] [5] [6] [7] . MDS is a generic name given to a group of diseases presenting with cytopenia and a preleukemic condition of unknown cause, and some patients with MDS progress to AML. Measurement of WT1 mRNA levels in the peripheral blood (PB) of patients with MDS was shown to offer useful information for the diagnosis of disease stage and assessment of prognosis, similar to AML patients.
WT1 mRNA expression levels in the PB and bone marrow (BM) increase as the MDS disease stage progresses and are correlated with the International Prognostic Scoring System (IPSS) score and World Health Organization (WHO) classification-based Prognostic Scoring System (WPSS) score [8, 9] . The increase in WT1 mRNA expression levels in the PB and BM also leads to greater risk of progression to AML. In addition, a relationship between WT1 mRNA expression levels in the PB and BM and chromosomal aberrations was also seen as they were both correlated with the proportion of myeloblasts and were high in a poor chromosomal karyotype group [10] .
This present study was designed to follow up 82 patients, who gave secondary consent, among 115 MDS patients registered in study ODK-0801 at 17 medical institutions listed in Table 1 . The patients were followed up for 5 years up to 2014 to analyze in detail the relationship between the WT1 mRNA expression level and prognosis.
Materials and methods

Ethics
This study was conducted in compliance with the ethical principles based on the Declaration of Helsinki, Pharmaceutical Affairs Law, relevant ministerial ordinances, notifications, and ethical guidelines related to clinical studies, and the protocols of this study. The approval of institutional review boards or ethics committees of each medical institution participating in this study was obtained beforehand.
Written consent was obtained from the patients after sufficient explanation from an investigator or subinvestigator, with the use of explanatory documents for the informed consent form, and after confirming that they fully understood the contents and were willing to participate in the study.
Patients
The 82 MDS patients studied (2008 Table 2 ). Note that the design of ODK-0801 was a one-point study, and thus the first Reference 10) . The current study is a follow-up to ODK-0801 and includes data on the prognosis of individual patients.
Methods
After study ODK-0801, from September 2010 we investigated whether the same patients were living or deceased once a year, as well as the disease stage, clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. For deceased patients, we investigated the date and cause of death. In addition, WT1 mRNA expression levels in the PB were measured according to the 2008 WHObased MDS subtype of individual patients at least once a year, and, if possible, they were also measured in the BM.
Measurement of WT1 mRNA levels
RNA was extracted from leukocytes in the PB and from nucleated cells in the BM using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and WT1 mRNA was measured using a WT1 mRNA Assay Kit (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) [11] . cDNA was synthesized from 1 µg of extracted RNA by reverse transcription using the random hexamer method. Levels of WT1 and GAPDH mRNA were calculated using real-time PCR of the synthesized cDNA. COBAS TaqMan48 (Roche Molecular Diagnostics, Pleasanton, CA, USA) was used in real-time PCR, and levels of WT1 and GAPDH mRNA in the samples were calculated, respectively, by simultaneous reactions of cDNA synthesized by reverse transcription and reference standards of known concentrations. The lower limit of measurement for this WT1 mRNA assay kit was 50 copies/µg RNA.
Statistical analysis
Differences between two groups of data of continuous variables were analyzed by Student's t-test. Differences between three or more groups of data on continuous variables were analyzed by one-way ANOVA with the Tukey-Kramer multiple-comparison test. Differences in categorical variables were evaluated using Fisher's exact test. Statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC). A Cox proportional hazard model was used to investigate survival time in MDS patients and its predictive factors and to estimate corresponding hazard ratios (HRs) and 95% confidence intervals (CIs). Both the categorical and continuous variables mentioned below were calculated based on the actual values stated in study ODK-0801.
When using the WPSS
The 6 multivariable predictive factors were the following categorical variables: gender (female: 0, male: 1), myeloblasts (< 5%: 0, 5-10%: 0.5, 11-20%: 1. The 6 multivariable predictive factors were the following continuous variables: white blood cell count (WBC), WT1 in the BM, blasts in the PB, hemoglobin (Hb), WT1 in the PB, and platelet count. Each parameter that continues was standardized by changing to average = 0 and dispersion = 1 after calculating the mean and the standard deviation (SD), and applying to the formula (data -mean)/SD in regard to each parameter.
When using the IPSS
The 6 multivariable predictive factors were the following categorical variables: gender (female: 0, male: 1), myeloblasts (< 5%: 0, 5-10%: 0. The 6 multivariable predictive factors were the following continuous variables: WBC, WT1 in the BM, blasts in the PB, Hb, WT1 in the PB, and platelet count. Each parameter that continues was standardized.
When using the Revised IPSS
The 7 multivariable predictive factors were the following categorical variables: gender (female: 0, male: 1), myeloblasts (< 2%: 0, 2%-< 5%: 1, 5-10%: The 7 multivariable predictive factors were the following continuous variables: WBC, ferritin level, lactate dehydrogenase (LDH) level, WT1 in the BM, blasts in the PB, absolute neutrophil count (ANC), and WT1 in PB. Each parameter that continues was standardized.
To investigate the relationship between WT1 mRNA expression levels in the PB and BM and survival time, a survival curve was determined using the KaplanMeier method, and the log-rank p value in TukeyKramer's honest significant difference (HSD) test was determined to examine homogeneity among groups. The level of statistical significance was set at p < 0.05 in all cases. RCUD: refractory cytopenia with unilineage dysplasia; RARS: refractory anemia with ringed sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RAEB-1: refractory anemia with excess blasts-1; RAEB-2: refractory anemia with excess blasts-2; 5q-syndrome: myelodysplastic syndrome with isolated del(5q); MDS-U: myelodysplastic syndrome, unclassifiable; RA: refractory anemia; RAEB: refractory anemia with excess blasts; RAEB-t: refractory anemia with excess blasts in transformation.
Results
Information about clinical and cytogenetic data
Information about clinical and cytogenetic data were obtained from 82 MDS patients (Table 3) .
As shown in Table 3 , in low-grade MDS, multilineage dysplasia and abnormal cytogenetics were not completely associated with clinical data (White blood cell count (WBC), Hemoglobin, Platelet count and Absolute neutrophil count (ANC)). However, risk group (IPSS, WPSS, and IPSS-R) were associated with clinical data. Significant difference (p < 0.05) was Table 3 Data as a function of specific clinical characteristics White blood cell count (/µL) observed only in Karyotype of ANC in low-risk MDS (RCUD and RCMD) of the WHO classification. On the other hand, significant differences were not observed in any items (WBC, Hemoglobin, Platelet count and ANC) in the RAEB group, a high-risk group.
Furthermore, in all the MDS patients, significant differences were observed (p < 0.05) in 3 items, WBC, Platelet count and ANC, in IPSS risk group, and significant difference was observed only in Hemoglobin in the WPSS risk group. In the IPSS-R risk group, a significant differences were observed in Hemoglobin and Platelet count.
Prognostic factors for survival time
Predictive factors of survival time were investigated based on the data at the time of registration in study ODK-0801. As a result, the WBC count in the PB (HR = 2.067, CI = 1.456-2.936, p < 0.0001), WPSS score (HR = 1.798, CI = 1.428-2.264, p < 0.0001), WT1 mRNA expression levels in the BM (HR = 1.667, CI = 1.220-2.277, p = 0.0013), blasts in the PB (HR = 1.307, CI = 1.074-1.590, p = 0.0075), and gender (HR = 2.883, CI = 1.250-6.648, p = 0.0130) were selected from the WPSS from the categories including gender, age, WT1 mRNA expression level in the PB, WT1 mRNA expression level in the BM, WBC count in the PB, Hb level, platelet count, blast count in the PB, myeloblasts, WHO subtype, blood transfusion dependency, chromosomal karyotype, and WPSS score (Table 4a) .
In a similar analysis using the FAB classification, the IPSS score (HR = (Table 4b) . When the IPSS-R was used instead of the IPSS in the analysis based on the FAB classification, the same prognostic factors were selected, except that the IPSS score was changed to the IPSS-R score [12] (Table 4c ). The range of each HR by which variable selection was made was 1.13 to 6.52. WT1 mRNA expression level in the BM was selected as a significant prognostic factor for survival time in both classifications.
Estimation based on the analysis of Cox proportional hazard models by IPSS-R risk category
Survival times were estimated by the five selected parameters in which WT1 mRNA expression levels varied (500, 50,000, 100,000, and 150,000 copies), as shown in Fig. 1 , whereas four other parameters in the analysis using the IPSS-R risk categories (IPSS-R score, WBC count in the PB, myeloblasts in the PB, and gender) were constant. The median survival period of patients with WT1 mRNA expression levels of 500, 50,000, 100,000, and 150,000 copies was more than 60, 45, 17.5, and 12 months, respectively, demonstrating a good correlation with prognosis. The survival time became shorter as the WT1 mRNA expression level in the BM was multiplied by higher factors (Fig. 1). 
Relationship between WT1 mRNA expression levels and overall survival rate
The 82 patients were classified into 3 groups based on their WT1 mRNA expression levels in the PB and BM; a survival curve (censored at the point of allo- 500 copies 50,000 copies 100,000 copies 150,000 copies geneic transplantation) was prepared using the KaplanMeier method, and the groups were compared for homogeneity in the log-rank test. WT1 mRNA expression levels in the PB were classified into the following 3 groups: < 50 copies/µg RNA; 50-10 4 copies/µg RNA; and 10 4 copies/µg RNA. WT1 mRNA expression levels in the BM were classified into the following 3 groups: < 500 copies; 500-10 4 copies; and 10 4 copies. When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, significant differences were detected between the < 500 group and 10 4 group and between the 500-10 4 group and 10 4 group for BM levels (p < 0.01). For WT1 mRNA expression levels in the PB, significant differences were also detected between the < 50 group and 10 4 group (p < 0.01). The overall survival rate differed significantly among the groups classified by WT1 mRNA expression levels in both the PB and BM, demonstrating a shortening of survival time with increasing WT1 mRNA expression levels (Fig. 2a) .
The survival time of 55 RA patients in the FAB classification was not significantly different when they were grouped according to their PB and BM WT1 mRNA expression levels (data not shown). The same analysis of 47 patients in the IPSS Int-1 group was assessed according to their WT1 mRNA expression levels, and a significant difference was detected between the < 500 group and 10 4 group and between the 500-10 4 group and 10 4 group for BM levels (p < 0.05). This finding indicates a shortening of survival time with increasing WT1 mRNA expression levels in the BM (Fig. 2b) . Conversely, the survival time of 56 patients in the lower-risk WPSS groups (very low, low, and intermediate) was not significantly different when they were grouped according to their PB and BM WT1 mRNA expression levels (data not shown). Further, when the survival period of 58 patients in the lowrisk IPSS-R groups (very low, low, and intermediate) was assessed according to their WT1 mRNA expression levels, no significant difference was detected in either the PB or BM (data not shown).
As shown in Fig. 3a , the conventionally defined 5-year probability of Leukemia-free survival (LFS) in 82 MDS patients was 77% in both PB and BM.
When we assessed the time of freedom from AML transformation in 82 MDS patients by WT1 mRNA expression level, significant differences were observed between the < 500 group and 10 4 group and between the 500-10 4 group and 10 4 group for BM levels (p < 0.01). In the case of WT1 mRNA expression levels in the PB, significant differences were also observed between the < 50 group and 10 4 group and between the 50-10 4 group and 10 4 group (p < 0.01). Examination of the time of freedom from AML transformation indicated that a high WT1 mRNA expression level (> 10 4 copies/µg RNA) was a strong prognostic factor for a short time to AML transformation (Fig. 3b) .
Relationship between WT1 mRNA expression levels and IPSS-R risk group
WT1 mRNA expression in PB and BM for each IPSS-R risk group were compared in the 82 patients, who gave secondary consent, among 115 MDS patients registered in study ODK-0801. A tendency for WT1 mRNA expression to increase in both PB and BM was observed in each IPSS-R risk group as the risk of transformation to AML increased from very low to very high. Significant differences (p < 0.05) in WT1 mRNA expression were observed in risk groups between very low and high, very low and very high, low and high, low and very high, and intermediate and very high in PB samples; and between very low and high, very low and very high, low and high, and low and very high in BM samples (Fig. 4) .
When lines indicating WT1 mRNA expression levels of 50 and 10 4 copies/µg RNA were drawn on scatter diagrams for the IPSS-R risk groups in this study, WT1 mRNA expression levels in the low and Intermediate groups were distributed widely from a low level of < 50 copies/µg RNA to a high level of 10 4 copies/µg RNA. In this study, the overall survival rate decreased significantly in the group with WT1 mRNA expression levels of 10 4 copies/µg RNA in the BM compared with the survival rate in the other two groups of Int-1 patients (Fig. 2b) .
Discussion
Tamura et al. [7] classified 69 MDS patients into 3 groups according to their WT1 mRNA expression levels in the PB in a retrospective analysis and compared the survival time and disease-free survival time. They reported that both survival time and disease-free survival time were shorter in the group with high WT1 mRNA expression levels compared with the groups with lower expression levels and that WT1 mRNA expression levels in the PB were an independent prognostic factor in MDS [7] . Our prospective study results support those findings.
Hematopoietic stem cell transplantation is indicated for patients with MDS in the IPSS Int-2 and high groups, provided that they meet the conditions for transplantation. If the conditions are not met, treatment with 5-azacytidine, decitabine, or high-potency chemotherapy is attempted. While immunosuppressive therapy is indicated for patients in the IPSS low and Int-1 groups, hematopoietic stem cell transplantation is indicated if frequent blood transfusions are required.
In MDS, the timing of transplantation has always been an issue. Cutler et al. [13] investigated the optimal timing for BM transplantation using myeloablative conditioning of human leukocyte antigen (HLA)-identical sibling donors in MDS patients and reported that a significant improvement in the survival rate could be expected following transplantation in the early stage after diagnosis in patients in the Int-2 and high-risk groups, although in the low-and Int-1-risk groups, the highest survival rate was expected by performing transplantation when disease progression was noted during careful monitoring of disease course after diagnosis rather than immediately after diagnosis. However, those results were restricted to HLAidentical sibling donor transplantation, and the quality of patients' lives after transplantation was not taken into consideration.
De Witte et al. [14] , on the other hand, investigated the results of transplantation in 374 MDS patients with RA or RARS using multivariate analysis and showed that, while the degree of pretreatment or donor type had no effect on the results of transplantation, transplantation in recent years, younger patient age, and a short period from diagnosis to transplantation may result in a better outcome. However, deterioration of the quality of life after transplantation and complications in the chronic stage were not mentioned in that report, and it is still difficult to make a decision on the indication for transplantation in the low and Int-1 groups.
WT1 mRNA expression levels in the Int-1 group were distributed widely from a low level of < 50 copies/µg RNA to a high level of 10 4 copies/µg RNA, as shown in Fig. 4 . In this study, the overall survival rate decreased significantly in the group with WT1 mRNA expression levels of 10 4 copies/µg RNA in the BM compared with the survival rate in the other two groups of Int-1 patients (Fig. 2b) . Patients with a WT1 mRNA expression level of 10 4 copies/µg RNA in the BM had a poor prognosis, which also supports the hypothesis that patients with high WT1 mRNA expression levels will have a poor prognosis (Fig. 1) .
Ommen et al. reported that the WT1 mRNA level in the BM is superior to that in the PB in predicting prognosis, as observed in AML patients from whom samples were available within 3 months prior to clinical relapse. They proposed the following monitoring method to identify differing relapse kinetics patterns: in the BM, almost 100% of clinical relapses can be predicted based on WT1 mRNA level measured in the period 3 to 4 months before relapse; and in the PB, 80% of the cases can be predicted based on the WT1 mRNA level measured bimonthly [15] .
The WT1 mRNA level in the PB is therefore an effective prognostic marker in patients with AML. The tumorigenesis of AML is thought to be at the stem cell level, suggesting that the measurement of the WT1 mRNA expression level in the BM is not necessary. However, the analysis in this study revealed that the WT1 mRNA expression level in the BM reflects trends in the effectiveness of treatment and the number of residual tumor cells. This finding indicates that the tumorigenesis of MDS is also likely to originate at the stem cell level, and thus the measurement of the WT1 mRNA level in the BM is an effective prognostic marker in patients with MDS.
In the treatment of IPSS Int-1 patients, transplantation is not the first-line treatment according to the guidelines of the Japan Society for Hematopoietic Cell Transplantation [16] , although it may be considered for patients who meet the transplantation conditions. However, the results of this study showed a poor prognosis in patients with high WT1 mRNA expression levels, particularly in those with > 10 4 copies/µg RNA, among patients in the Int-1 group, who are thought to be at lower risk, suggesting that transplantation should be performed in this group, similar to Int-2 patients.
In the IPSS-R very low and low risk subgroups encompassed those who had been classified as IPSS low and Int-1. The IPSS-R intermediate category was composed of about 75% IPSS Int-1 [12] . So, in the treatment of IPSS-R Low and IPSS-R Intermediate patients with WT1 mRNA expression level of 10 4 copies/µg RNA may be considered as patients who are indicated to be in the transplantation setting.
On the basis of the above results, it is concluded that mRNA expression levels of WT1 in the PB and BM of MDS patients are useful prognostic indicators and can contribute to determining the appropriate therapeutic strategy, including allogeneic hematopoietic stem cell transplantation, which is the only radical cure for MDS. Furthermore, the measurement of WT1 mRNA expression levels is expected to contribute to the improvement of prognosis, such as prolongation of survival time, in MDS patients.
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